Imamoto A, Beltrán L M, DiGiovanni J
University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Smithville 78957.
Mol Carcinog. 1991;4(1):52-60. doi: 10.1002/mc.2940040109.
A single topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA) to mouse skin decreased 125I-labeled epidermal growth factor (EGF) binding in epidermal membrane preparations within 1 h while 1,8-dihydroxy-3-methyl-9-anthrone (chrysarobin) gradually reduced binding with maximum inhibition at 15 h. Subsequently, 125I-EGF binding increased to approximately 200% of control in epidermal membrane preparations from both TPA- and chrysarobin-treated mice. A single application of TPA but not chrysarobin resulted in a rapid translocation of protein kinase C (PKC) to the membrane; however, treatment with both promoters ultimately led to a time-dependent loss of PKC activity in both membrane and cytosol fractions. The initial inhibition of 125I-EGF binding was sustained for at least 24 h after single and multiple treatments with both promoting agents. Acid washing restored EGF binding to control levels in membrane preparations obtained 24 h after a single application, whereas acid washing of membrane preparations obtained 24 h after a second application of TPA or chrysarobin increased binding (2.5-fold and 1.5-fold that of the control, respectively). The presence of increased amounts of ligands for the EGF receptor in tumor promoter-treated epidermis was initially confirmed in 125I-EGF binding competition experiments using NRK-49F cells. A single topical application of TPA or chrysarobin induced elevated levels of transforming growth factor-alpha (TGF-alpha) mRNA at 6 h or 15-24 h, respectively. Elevated levels of a TGF-alpha precursor (21 kDa) were subsequently observed in cytosol and membrane preparations after single and multiple applications of TPA or chrysarobin. These results suggest that repeated topical application of tumor promoters may lead to sustained loss of a negative-feedback mechanism involving phosphorylation at Thr-654 of the EGF receptor by PKC. The concomitant elevation of ligands, such as TGF-alpha, may provide a mechanism for sustained cell proliferation essential for skin tumor promotion.
单次将12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA)局部涂抹于小鼠皮肤,1小时内可降低表皮膜制剂中125I标记的表皮生长因子(EGF)结合,而1,8 - 二羟基 - 3 - 甲基 - 9 - 蒽酮(柯桠素)则逐渐降低结合,在15小时达到最大抑制。随后,来自TPA和柯桠素处理小鼠的表皮膜制剂中,125I - EGF结合增加至对照的约200%。单次涂抹TPA而非柯桠素可导致蛋白激酶C(PKC)迅速转位至膜;然而,两种促癌剂处理最终均导致膜和胞质溶胶组分中PKC活性随时间丧失。两种促癌剂单次和多次处理后,125I - EGF结合的初始抑制至少持续24小时。酸洗可将单次涂抹24小时后获得的膜制剂中的EGF结合恢复至对照水平,而第二次涂抹TPA或柯桠素24小时后获得的膜制剂酸洗后结合增加(分别为对照的2.5倍和1.5倍)。在使用NRK - 49F细胞的125I - EGF结合竞争实验中,最初证实了肿瘤促癌剂处理的表皮中EGF受体配体数量增加。单次局部涂抹TPA或柯桠素分别在6小时或15 - 24小时诱导转化生长因子 - α(TGF - α)mRNA水平升高。单次和多次涂抹TPA或柯桠素后,随后在胞质溶胶和膜制剂中观察到TGF - α前体(21 kDa)水平升高。这些结果表明,重复局部涂抹肿瘤促癌剂可能导致涉及PKC对EGF受体Thr - 654磷酸化的负反馈机制持续丧失。诸如TGF - α等配体的同时升高可能为皮肤肿瘤促进所必需的持续细胞增殖提供一种机制。